Monday Monitor

KEDM Weekly


Theme of the Week

 

Wound Care

Modern wound care is remarkably fragmented. Dozens of companies claim superior healing with limited clinical evidence. Accelerated pathways allow products onto the market with minimal data. All wounds and skin types are different, and no one knows how a particular wound would have healed without intervention. Ask 10 wound-care doctors how to treat the same ulcer, and you may get 10 different answers.

Normally, wound care would be too niche for us. Then the numbers forced us to pay attention. The industry grew from $256 million in 2019 to more than $10 billion in 2024. That is not incremental growth. That is a meme-stock chart from 2021.

Five years ago, the priciest skin substitute cost about $1,000 per square inch. Today, several products are listed at over $21,000. When you reimburse based on price, people eventually decide that the price should be very high.

 

Historically, skin substitutes were reimbursed at ASP + 6%. New products had no ASP reference point, so manufacturers simply set whatever number they liked. Six months later, they could rename and relaunch the product, reset the pricing window, and repeat the cycle.

The incentives were clear. Apply large grafts to tiny wounds. Treat minor wounds on patients, unlikely to heal. Repeat the same procedure every week. Sprinkle in a few illegal kickbacks and luxury steak dinners, and the American dream was alive and billing. One Arizona couple managed to rack up $1.2 billion in bills before pleading guilty.

Take a chronic non-healing foot ulcer. A doctor could apply a “skin substitute,” bill Medicare at thousands of dollars per application, repeat weekly, and voilà – the patient might still have the ulcer, but the clinic got a new Porsche…

 

Subscribe For More Event-Driven Opportunities

 


Kuppy’s Tweet of the Week

 


Kliff Note of the Week

 

Inflection Monitor: Trump’s EPA terminates Obama’s 2009 “endangerment finding” declaration, which determined that CO₂ and other greenhouse gases endanger public health and welfare and provided the legal basis for regulating greenhouse gas emissions under the Clean Air Act.

This is the ruling that Ford (F) and General Motors (GM) were waiting for, and which we highlighted in last year’s automotive write-up.

 

 


 

Spin-off Monitor: An Indian $29bn market-cap, diversified natural resources and energy group, Vedanta (VEDL IN), updated on the demerger. The company is in the process of demerging into five specific commodity companies to basically eliminate conglomerate discount.

The listing of the entities is planned for this March, and each shareholder will receive 1 share in each listed entity. The main business units are cyclical, yet the company as a group has had strong profitability. Worth looking at.

 


 

Newsletter Short Monitor: Solvay (SOLB BB) has clear short-term potential in our view. It’s still holding up decently in bad markets, but that’s mainly due to its 8.5% dividend.

End markets remain horrible, and 2026 is going to be another challenging year. We don’t think that the company’s cash generation will be sufficient to sustain its dividend.

The upcoming FY results might make for a good moment to cut it, but that would not be well received by the market.

 

 


 

13D Monitor: Capital Federal Financial (CFFN) is being targeted by HoldCo AM, which wants improved capital returns. A good moment to go active, as Capitol Federal is finally showing some real signs of life.

Good recent EPS growth on rising interest income, falling funding costs, and a steadily improving net interest margin. Deposit growth is picking up (mainly commercial deposits), efficiency is improving, non‑interest income is growing, and CFFN is still doing buybacks below book value.

Yes, it’s still a low‑ROE, mortgage‑heavy regional bank, but the trend seems to have turned. 0.94x BV and ~11x P/E.

 

 


 

M&A Monitor: UniFirst (UNF) is once again in play as Cintas recently renewed its long‑running effort to buy the company. UniFirst confirmed it is now actively reviewing Cintas’ latest $275 p/s offer.

While the Croatti family’s control and dual‑class structure mean nothing can happen without their approval, Cintas has been pushing for years, and the current discussions feel more serious than past attempts.

We might see an offer of >$275 p/s, which, honestly, would be a good deal.

 

 


 

Other Interesting ED Action: ICON Plc (ICLR) traded down 40% after reporting the results of an internal investigation into its accounting practices, which could lead to a 2% restatement of revenue.

The earnings impact is likely larger than 2% (10% of EBITDA if you assume a 100% drop through margin), but this feels like an overreaction. The $9bn EV is now well below the $12bn they paid for PRA only 4 years ago.

CROs are seen as potential AI losers by the market, so buyer beware.

 


 

KEDM Event Driven Monitor scans over 20 corporate events for market moving information and distills them into our propietary “Kliff Notes.”  One profitable trade should more than cover an annual subscription and access to the Event Driven chatroom!

 

Subscribe For More Event-Driven Opportunities

WANT FREE WEEKLY UPDATES?

Subscribe to our weekly email newsletter
The Monday Monitor to get free KEDM insights sent right to your inbox.

You’ll get the KEDM Event of the Week, KEDM’s Kliff Note and Chart of the Week, and our selection of the week’s best research, commentary and more from others in our Friends of KEDM section.

This field is for validation purposes and should be left unchanged.
Name(Required)